Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.16 USD
Change Today +0.37 / 4.75%
Volume 348.3K
SCLN On Other Exchanges
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Friedhelm Blobel Ph.D.

Chief Executive Officer, President, Executive Director and Member of Business Development Committee,SciClone Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 board members in 1 different organizations across 1 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Friedhelm Blobel, Ph.D. has been the Chief Executive Officer and President at SciClone Pharmaceuticals, Inc. since June 2, 2006. Dr. Blobel has more than 20 years experience in the pharmaceutical and healthcare industries. Dr. Blobel served as an Interim Acting Chief Financial Officer of SciClone Pharmaceuticals, Inc. from May 31, 2013 to July 15, 2013. Dr. Blobel served as Acting Chief Financial Officer of SciClone Pharmaceuticals Inc. from May 1, 2008 to December ...

Read Full Background

Corporate Headquarters*

950 Tower Lane
Foster City, California 94404

United States

Phone: 650-358-3456
Fax: 650-358-3469

Board Members Memberships*

Chief Executive Officer, President, Executive Director and Member of Business Development Committee


Universität Hohenheim
Unknown/Other Education
Universität Stuttgart

Other Affiliations*

Annual Compensation*

Total Annual Compensation$566,500

Stock Options*

Restricted Stock Awards$31,640
All Other Compensation$15,691
Exercisable Options2,008,333
Exercisable Options Value$11,680,374
Unexercisable Options391,667
Unexercisable Options Value$1,545,626
Total Value of Options$13,226,000
Total Number of Options2,400,000

Total Compensation*

Total Annual Cash Compensation$1,024,061
Total Short Term Compensation$566,500
Other Long Term Compensation$47,331
Total Calculated Compensation$1,514,781
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLN:US $8.16 USD +0.37


Rajat Rai Chief Executive Officer
Akorn, Inc.
Arthur P. Bedrosian J.D.Chief Executive Officer, Director and Chairman of Strategic Planning Committee
Lannett Company, Inc.
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
Allan Oberman Chief Executive Officer and Director
Sagent Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCICLONE PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at